Department of Medicine, Section of Hematology/Oncology, University of Illinois at Chicago, 840 S Wood St Rm 839, M/C 713, Chicago, IL 60612, USA.
Cancer Chemother Pharmacol. 2012 Apr;69(4):1113-5. doi: 10.1007/s00280-011-1796-4. Epub 2011 Dec 7.
The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC-NCIC CE.3) trial, and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences in the length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.
在一项随机 III 期临床试验（EORTC-NCIC CE.3）中证实了 6 个周期辅助替莫唑胺的获益，在联合替莫唑胺和放疗后，该疗法是新诊断胶质母细胞瘤患者的标准治疗方法。我们将讨论临床实践和国家研究（例如 RTOG 0825）中辅助治疗时间长度的差异，通常将 EORTC/NCIC 研究中的治疗时间长度延长一倍，并与实体瘤的历史辅助试验相关联。
